RefleXion Medical

Executive Summary

RefleXion Medical is a private biotechnology company pioneering a novel biology-guided radiotherapy (BgRT) platform that integrates real-time PET imaging with a linear accelerator. This enables dynamic targeting and treatment of multiple tumors, including moving lesions, in a single session, addressing a critical unmet need in radiation oncology. The company's technology sits at the intersection of diagnostics and radiopharmaceuticals, creating a new paradigm for personalized cancer therapy. Currently, RefleXion's X1 system has received FDA clearance for certain indications, and the company is actively expanding its clinical footprint through ongoing trials and partnerships. With its innovative approach, RefleXion has the potential to significantly improve treatment precision and patient outcomes, particularly for metastatic disease. The company's progress positions it as a leader in the next generation of radiotherapy, though it faces competition from established radiation therapy players and emerging modalities. Overall, RefleXion represents a compelling investment opportunity in the precision oncology space, contingent on successful commercialization and regulatory expansion.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for new tumor sites (e.g., lung, prostate) expanding indications for BgRT65% success
• Q3 2026Publication of pivotal clinical trial data demonstrating efficacy and safety in metastatic cancer patients70% success
• TBDStrategic partnership or licensing agreement with a major radiopharmaceutical or oncology company50% success